semaglutide santa rosa July 29, 2024: FDA issued

GLP-1 medications create a window an opportunity where dietary change feels more achievable because the biological noise of constant hunger is finally quieter

Based on current phase 3 TRIUMPH trial timelines, a regulatory submission to the MHRA is not anticipated before 20262027 at the earliest, with a possible marketing authorisation in 20272028 and NHS availability potentially from 2028 onwards, subject to NICE appraisal

Excess adiposity, particularly visceral fat, is associated with metabolic dysfunction that may affect hormone regulation

IGF supports the maturation process of luteinization because of increasing LHR density and decreasing preovulatory FSHR expression